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ABSTRACT
A PHASE II TWO STAGE CLINICAL TRIAL DESIGN TO HANDLE LATENT
HETEROGENEITY FOR A BINARY RESPONSE
Christopher N. Barnes
April 15,2010
Phase II clinical trial are generally single arm trial where a homogeneity
assumption is placed on the response. In practice, this assumption may be violated
resulting in a heterogeneous response. This heterogeneous or overdispersed response can
be decomposed into distinct subgroups based on the etiology of the heterogeneity. A
general classification model is developed to quantify the heterogeneity. The most
common Phase II trial design used in practice is the Simon 2-stage design which relies on
the assumption of response homogeneity. This design is shown to be flawed under the
assumption of heterogeneity with errors exceeding the target trial errors. To correct for
the error inflation, a modification is made to the Simon design if heterogeneity is detected
after the first stage trial conduct. The trial sample size is increased using an empirical
estimate for the variance inflation factor and the trial is then completed with design
parameters constructed through the posterior predictive Beta-binomial distribution given
the first stage results. The new design, denoted the 2-stage Heterogeneity Adaptive
(2HA) design, is applied to a two subgroup problem under latent heterogeneity. Latent
heterogeneity represents the most general form of heterogeneity, no information is known
prior to trial conduct. The results, through simulation, show that the target errors can be

v

maintained with this modification to the Simon design under a wide range of
heterogeneity.
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CHAPTER 1

INTRODUCTION
The primary assumption for most Phase II single arm binary trials is the
assumption of response homogeneity. Response homogeneity is defined as the variance
of the response being bounded by the variance of a binomial distribution given a response
rate,

Jr

(Simon 1989). Many single arm Phase II trials do not adhere to this assumption

in practice. When the variance of the response, denoted x which corresponds to the
number of patients with a positive response, exceeds the binomial variance,

v (x) > nJr ( 1-

(1)

Jr) ,

the response is deemed a heterogeneous response (Williams 1982; Yamamoto and
Yanagimoto 1994; Collet 2003). The common structure of this heterogeneous response
is a response profile of disjoint subgroups,
subgroups where

Jri is

1t

= (Jr1 , Jr2 , ••• , Jrg ) , for i = 1,2, ... , g

the response probability for the ith subgroup and there exists at

least two distinct subgroup response rates,

Jri

*- Jri , for some i *- i'. In contrast, the

response in a homogeneous population follows a single response rate, where

Jr

= Jri = Jri ,

for all i *- i'. Subgroup membership is defined by a single or multiple set of markers
(London and Chang 2005; Thall and Wathen 2008; Behrendt and Gehan 2009). The
markers can be composed of clinicopathologic features such as age, gender, diagnostic
1
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or prognostic markers such as baseline insulin levels or single/multiple genomic markers
such as the BRCAI gene in Breast cancer.
A common practice in clinical trials when heterogeneity is assumed and the
markers are known is to use a simple or weighted mean of the response profile of the
subgroups to compute a single response rate which adheres to the homogeneity
assumption (Green 1982; Gadbury and Iyer 2000; Emerson, Kittelson et al. 2007;
Emerson, Kittelson et al. 2007; Ayanlowo and Redden 2008; Thall and Wathen 2008;
Tuma 2008; Wathen, Thall et al. 2008). The weights are derived from either the known
population proportions of each subgroup or estimated from a random sample of patients.
This leads to one of two averaging constraints on the response profile. Let
T

Jrr

for

={O, I} , the null response rate and alternative response rate respectively, be the

response rate, then the average constraints are defined as

(2)

or

I

WiJrr;

= Jrr

(3)

i=1

for simple average and g subgroups and for a weighted average, where

Wi

= nj / n is the

weight for subgroup i, nj is the number of patients in subgroup i for a total of
g

I

ni

=n patients in the sample, respectively.

i=1

2

Using methods that rely on the homogeneity assumption when heterogeneity is
true will lead to biased inferences (Russek-Cohen and Simon 1997), incorrect early
stopping of the trial (Thall, Wathen et al. 2003; Thall and Wathen 2008; Wathen, Thall et
al. 2008) or a subsequent failure of the Phase III trial resulting in a substantial loss of
resources (Rosner, Stadler et al. 2002; Stadler 2007; Tuma 2008). This is primarily due
to the departure of the trial data distribution from the model distribution from which the
trial parameters are constructed, the binomial distribution. It will be shown that this
approach, when applied to the most common Phase II trial design, the Simon 2-stage
trial, will result in unbounded errors, false positive or false negative trial conclusions,
dependent on a combination of the magnitude of difference between the subgroup
responses and the difference in subgroup weights.

A second method when heterogeneity is present is to conduct multiple trials, one
for each subgroup. This will result in a heavy strain on trial resources especially for early
development Phase II trials. Due to possible low patient accrual in one or more trials,
trials may not be completed; losing valuable information on the treatment effect over the
entire population. Conducting multiple trials ignores a fundamental assumption of the
motivation for a single trial; all patients share a common disease state. It is assumed that
the response rate in one subgroup will be partially correlated with the response rate in the
other subgroups. Secondly, the subgroups must be known in advance of the trial conduct
to conduct multiple trials which is not always a practical situation.
In the last few years, multiple methods have been developed to account for
response heterogeneity by quantifying the structure of the subgroups in the test statistic

3

(London and Chang 2005; Thall and Wathen 2008). Two examples are briet1y
mentioned. The simplest form, the unconditional stratified test, assumes a stratified
response based on known subgroups and modifies the Binomial test statistic into the form
of a stratified log-rank test (London and Chang 2005). The resulting test has a global
hypothesis, either the compound/treatment provides efficacy evidence to move onto
further targeted Phase II testing or Phase III testing or it does not.
Bayesian methods have also been developed which rely on hierarchical models or
ANCOVA models to model the structure of the subgroups (Thall, Wathen et al. 2003;
Wathen, Thall et al. 2008). The Bayesian methods employ the desirable characteristic of
local hypothesis tests, rejection of the efficacy hypothesis on a subgroup level allowing
some subgroups to succeed while others may fail. Secondly, the Bayesian methods
minimize the overall sample size as compared to running multiple trials by sharing
response information across the subgroups when making decisions on individual
subgroups. Drawbacks are that Bayesian methods will use considerably more
computational resources and do not rely on fixed sample size estimates. The limiting
drawback to implementing these designs in actual trial conduct and the remaining
methods described in the literature is that all the methods rely on the assumption that the
composition of the subgroups is known prior to trial conduct. The methods provide no
methodology for when the subgroups are latent prior to trial conduct.
Recently, there has been a shift in focus to randomized Phase II designs to help
mitigate heterogeneity in the response (Lee and Feng 2005). Randomized trials can
provide a mechanism to estimate the source of the heterogeneity and the type of
4
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heterogeneity. A major drawback to the randomized designs is the substantial increase in
trial resources, usually a doubling of trial resources to reject a global hypothesis. The use
of a randomized design is not always practical at such an early stage of estimating
treatment efficacy due to patient accmal issues and will not be considered in this paper.
In practice, the composition of the subgroups is not known or only partially
hypothesized. Latent subgroups are a more common problem in clinical trials and may
provide an etiology for the high failure rate of Phase II trials. Phase II trials are not
conducted unless there is substantial ex vivo evidence of compound/treatment efficacy.
In practice, many Phase II trials still fail when this evidence is present; presenting the
issue of whether the trial failure rests on inadequate efficacy of the compound/treatment,
inadequacy of the trial design, or inaccurate estimates of the hypothesized response. We
focus on the second issue, inadequacy of the trial design as a possible solution to the high
failure rate of Phase II trials.
Before developing a new trial design, the stmcture to heterogeneity must be
quantified. We have developed a classification model to quantify response heterogeneity,
through the subgroups, into three classes, historical response heterogeneity (HRH),
assumed response heterogeneity (ARH) and general response heterogeneity (GRH).
These classes can help to detect when a trial may fail due to heterogeneity.
HRH is composed of known subgroups. In simplest terms, the subgroups are
known either from responses to similar treatments, known biological motivations or can
be estimated from the response in the control group of a randomized trial design denoted
as the null response. Under HRH, the null response, e.g. response under no treatment, is
5

heterogeneous and the treatment effect is homogenous resulting in a heterogeneous
response structured by the heterogeneity of the null hypothesis response.
In contrast, ARH assumes a homogeneous null response and a heterogeneous
treatment effect. Under ARH, no known or latent subgroups exist on prior treatment, but
a Treatment x Marker effect is identified causing the treatment and thus response under
the treatment, denoted the alternative response, to vary by this Treatment x Marker
subgroup composition. In both the previous classes, the alternative responses are unique.
Each disjoint subgroup can be identified from a unique alternative treatment response
rate.
A generalization of the first two classes is general response heterogeneity. GRH
is composed of possibly both heterogeneous historical response and heterogeneous
treatment effects. GRH does not always result in uniquely identifiable subgroups through
the alternative response, but results in unique subgroups through the source of the
heterogeneity. Multiple different combinations of null response and treatment effect can
result in the same alternative response.
Under the context of a single stage design, in order to determine the composition
of subgroups, a pre-clinical analysis would have to be conducted on a set of patients
which would entail exposing the patients to the compound/treatment to determine
response. A second set of patients would be used in the resulting trial. This is not an
optimal use of trial resources. The first set of patients, in effect, can be construed as a
separate trial in which the data is thrown away; not providing response information for
use in the actual trial. A more suitable solution would be to conduct the "pre-clinical"

6

analysis during the trial; hence, minimizing time and patient resources. No information
would be lost, all patients that undergo treatment would used in estimating response. The
two stage designs of Simon provide a natural break for this analysis, between stages.
While the two stage process is a suitable solution to this problem and comprises the
majority of all conducted Phase II trials, the use of the binomial distribution as the model
distribution is not appropriate.
We develop a two stage design which begins as the popular Simon 2-stage design
and is adapted to accommodate heterogeneity if heterogeneity is identified between the
conduct of the two stages. If no source of heterogeneity is identifiable, the trial continues
on under the Simon design; otherwise an adaption is made and the trial is evaluated using
new adaptive trial parameters.
The paper is organized as follows. Chapter two introduces the basic two stage
design of Simon, the heterogeneity model and trial error construction. Chapter three
provides a literature review of the current methods to handle heterogeneity with nonlatent heterogeneity. Chapter four introduces the main components of the new trial
design, subgroup identification, heterogeneity tests, the trial's model distribution, and
finally, the trial algorithm. Chapter five investigates the operating characteristics of the
Simon design and new trial design under heterogeneity with concluding remarks and
future direction in Chapter six.

7

CHAPTER 2

SIMON DESIGN, HETEROGENEITY MODEL AND ERRORS

2.1

Simon Phase II Designs
The basic two stage binary Phase II trial design was first implemented by Gehan

(Gehan 1961). Shultz modified the Gehan design to require a minimum of at least one
response in the first stage with equal size sample sizes in both stages (Schultz, Nichol et
al. 1973). The Gehan design can allow no response in the first stage. Simon later
popularized the Shultz design by allowing unequal size sample sizes in the stages and
constructing a search algorithm to determine the optimal and minimax designs which
meet a set of sample size optimization criteria (Simon 1989).
For simplicity, the term treatment denotes a compound, treatment or regimen. Let
x be the realized data in stage one with

(lj, n)) as the critical value and sample size for

stage one, and y be the realized data in stage two with

(r, n) as the critical value and

sample size for stage one and two combined. The trial parameters, (lj, nl' r, n) , are
constructed to estimate if the trial response rate under treatment,

1[,

is greater than or

equal to a clinically relevant target response rate, denoted the alternative response,
1[)

= 1[0 + t5 where

1[0

is the null response under no treatment and t5 is the treatment effect,

or formally, Ho: 1[ < 1[) vs. H) : 1[ ~ 1[), the null and alternative hypothesis respectively.
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If the sum of responses for the treatment in the first stage is not larger than the
stage one critical value, x:::; fj , the trial is stopped for futility; otherwise, the trial
proceeds to stage two enrolling an additional n - n l patients. Once all of the patients
have been evaluated, the sum of responses over both stages is compared to a second
critical value. If the sum of responses is not larger than the stage one + stage two
combined critical value, x + y :::; r , then the treatment is estimated to not have the desired
effect; otherwise, the novel treatment is estimated to be promising with a response rate of

The construction of the parameters of the trial,

(fj, n], r, n) ,

is dependent on the

target errors of the trial known as the type I error or size of the trial, a, and type II error
or I-power of the trial,

f3.

As such, the power of the trial is 1-

f3.

The critical values

and sample sizes for each stage are chosen from a set of possible designs constrained to
satisfy the type I and type II errors per
rnin( n[ ,r)

P (reject Hoi Jr = JrT )

= Bin (fj In" JrT ) +

I

bin (x Inl' JrT ) Bin (r - x Inl' JrT

)

r:::::'l+!

where bin is the binomial probability mass distribution and Bin is the binomial
cumulative distribution for treatments T

= {O, I} , the null and alternative hypothesis or

null and alternative response rate, respectively.
In practice to determine the parameters, n], n, fj, r , a sample size for stage I is first
chosen such that P(reject Ho

ITC = TCO,N] =n

l)

E

9

(.50, .80), also known as the probability of

(4)

early termination (PET). Using an iterative algorithm, given (n1' fj) , a total sample size is
selected to satisfy (4) under the pre-specified target type I and type II errors. This
process is repeated to find a set number, say 50, solutions that satisfy the error
constraints. Two of the solutions are then selected as the minimax and optimal designs.
The optimal design is the design that minimizes the expected sample size,

EN(Ho)

= n1 + (1- PET) ( n -11,),

(5)

under the null hypothesis over all possible designs and the minimax design is the design
that minimizes EN over all designs with the minimum total sample size, n.
Under a Simon design with no heterogeneity, no type I error is spent in the first
stage. This is due to the single bound of the critical value. The bound is for futility only.
Onl y a percentage of power is spent in the first stage. This is evidenced in the form of (4)
where the second component on the right hand side is a weighted sum weighted by the
"power" spent in the first stage. Most Phase II designs follow this approach, only a
futility bound in the earlier stages, since the primary goal of a Phase II trial is to estimate
if the treatment is promising for further testing, not to establish is the treatment is
efficacious.

2.2

A Model for heterogeneity
Response heterogeneity in a population can be modeled by deconstructing the

response rate into subgroups to form a response profile,
g subgroups where

lZ'i

1T = (lZ'1' lZ'2'"'' lZ'g)

,composed of

is the response rate for the ith subgroup and there exists

10

lZ'i f:. lZ'i'

for some i -:j:. i'; in contrast,

iC;

= iC;'

for all i -:j:. i' in a homogeneous population. The

resulting subgroup model provides the basic platform to compare methodology for
heterogeneous responses.

Let

11'T

= (iCT I' iCr 2'· •• , TCT g ) be the vector of subgroup responses for

i = 1,2, ... , g subgroups where
T

= {O, I}.

T

=0

response, and T

iCT ; is

the response rate in subgroup i for treatment

denotes the known standardlhistorical treatment response, e.g. the null

= I denotes the hypothesized experimental treatment response, e.g. the

alternative response.
In addition, let the baseline historical response rate for the historical response
profile be denoted by iC~

= arg min (iCo; ) . Furthermore, let TJ; be the prognostic response
g

heterogeneity between subgroup i and the baseline historical response,

I;

be the

predictive heterogeneity in treatment effect over the baseline treatment effect,
5* = arg min ( 5..;) where

5..; are the treatment effects for each subgroup, such that,
(6)

where 0 ~ iCT ;

~

1 ,defines a subgroup mixture model for heterogeneity (Barnes and Rai

2010). 10 is a membership indicator.

The historical response heterogeneity, TJ;, is a fixed prognostic effect while the
treatment heterogeneity, I;, is a predictive random effect. Using equation (6), the
11
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classification of response heterogeneity rests on the structure of the historical response
profile and the treatment effect profile. To quantify the range of response heterogeneity,
three classes, historical response heterogeneity (HRH), assumed response heterogeneity
(ARH), and general response heterogeneity (GRH), are constructed. For all i"# iI,

defines the HRH class and

defines the ARH class. In both classes, the experimental treatment response rates are
umque.
The third class, GRH, relaxes the unique response constraint. A mixture of prognostic
and predictive heterogeneity can result in non-unique experimental responses. The
etiology of each subgroup's heterogeneity is the basis for the subgroup construction and
is assumed to be unique. GRH is defined as follows. There exists some i"# i for which
I

(9)
In equation (7), a known covariate exists for which a prior historical response profile
can be constructed. The prior distribution of historical response rates, given the historical
covariate, is hypothesized to be consistent in the current trial. Heterogeneity in the
experimental response profile is attributed to the different known historical response
rates,

!COi

"#

!COi"

The treatment effects are homogeneous across the subgroups, ~

In contrast to HRH, the heterogeneity in equation (8), is quantified through
12

= ~, .

-_._------------------------------

heterogeneous treatment effects,
homogeneous,

1[Oi

~

1:-

~

,

where the estimated historical response rates are

= 1[Oi'. The heterogeneity is measured by the inequality of the

treatment effects between subgroups due to a covariate-treatment interaction as opposed
to the inequality of historical rates as in (7).

The general form of response heterogeneity, GRH, is a composite of both of the
previous classes of response heterogeneity. The general form (9) occurs when both the
historical response rates and treatment effects are hypothesized to be heterogeneous. For
example, under a three subgroup model, historically gender,
historical response rates,

1[01

= 1[02 = 1[OM ' and

1[03

(M, F), leads to different

= 1[OF where

1[OM 1:- 1[OF.

A biomarker

present in males is hypothesized to lead to a further differentiation of response rates, male
biomarker present and male biomarker absent, resulting in the following three possible
response models,

1[1I
1[01

= 1[02

1:-

1[03

and

1:- 1[12 1:-

1[11: 1[12

= 1[13

1[11 -1[12

1:- 1[13

{

The prognostic heterogeneity differs between gender,
heterogeneity only affecting the males,

'I '2 and '3 = o.
1:-

1[13

171

= 172 1:-173 , with a predictive

The first possible

experimental response model results in three unique response rates. While the remaining
two models result in two unique response rates with the effect of the male biomarker,
present or absent, providing the same experimental response rate as for females. When
no information is known about the structure of the heterogeneity, it is appropriate to
13

(10)

assume a general class stmcture. For this reason, the focus, in evaluating a new trial
design under latent heterogeneity, will rest on the GRH class of heterogeneity.

2.3

Heterogeneity model example

To illustrate the different classes of heterogeneity, the following hypothetical
example is provided. A trial is conducted to determine the response rate of dmg A to
treat early to moderate stage colon cancer, stage I-III. The researchers wish to test
Ho : Ir = Iro =.3 against HI : Ir >.3 with a target treatment effect of

the alternative response of
g

Irl

5 =.2 resulting in

=.5. Table lea-d) provides four possible scenarios under a

= 3 subgroup trial for different groups of researchers testing the same dmg. For

simplicity, the sample sizes of the subgroups are assumed to be equal.

The first scenario, table 1a, is an example of HRH. Research group I knows that
historically Dmg A leads to a response profile based on cancer stage for a similar
disease, breast cancer. This prognostic difference is assumed to be consistent in the
current trial due to the similarity of pathways being targeted between the two cancers.
The historical response profile for the standard treatment is
Teo = (lrOI ' Ir02 ' Ir03) = (.4, .3,.2) with lio =.3 constmcted from a baseline historical

response rate of Ir~ =.2 and a historical heterogeneity effect of 11 = (771,772,773 ) = (.2, .1, 0).
The objective is to test for a common treatment effect, () = ( ~ , 52 ,63 ) = (.2, .2,.2) such
that

T

=(TI , T2 , T3 ) =(0,0, 0), in a historically heterogeneous response resulting in the

experimental response profile

1t1

= (lrll,lrI2,lr13) =(.6,.5,.4) with li1 =.5.
14

The second scenario is an example of ARH, table lb. Group II contends that
there is no historical precedent for the usage of drug A on colon cancer, but hypothesize
a predictive difference based on a combination of two biomarkers resulting in three
clinically relevant subgroups, both biomarkers present, both absent and one present. The
response profile for the standard treatment is homogeneous,

1fo

= (.3, .3,.3)

with 11 = 0,

and it is the inequality of the treatment effect that is the source of the heterogeneity,

() =(.3, .2,.1)
1f[

such that

= (.6, .5,.4) with

7[[

'T

=(.25, .15, .05) , leading to an experimental response profile of

=.5.

The third example is an example of GRH, table Ie. Group III suspects that there
is both a prognostic effect based on cancer staging and a predictive effect based on the
biomarkers. There is both a heterogeneous historical treatment effect, 11 = (.33, .03, 0)
such that
'T

1f[

1fo

= (.51, .21, .18),

and heterogeneous treatment effect with

=(0, .20, .03) such that () =(.09, .29, .12).
=(.6,.5,.4) with

7[[

The experimental response profile is then

=.5.

The fourth group hypothesizes a more complex interaction between cancer
stage and biomarker status as a combination of HRH and ARH only affecting a
subsample of the subgroups, table ld. Historically, the researchers feel evidence only
provides a two subgroup prognostic difference in the efficacy of the drug, stage I vs.
Stage II-III with the status of the biomarker only affecting the second group, Stage II-III.
This results in

1fo

= (.35, .275, .275) with 11 = (.075,0, 0). The interaction between

15

biomarker status and the second prognostic subgroup leads to
experimental response profile of

1t]

= (0, .15, 0) for an overall

T

= (.55, .55,.40) with treatment effect profi Ie

o'-(
- .70
_ ,. 7T
_ ),. 17-)
_) .
Table 1 Numerical example of three classes of response heterogeneity.

*

7rs

'7;

.20
.20
.20

.20
.10
0

*

a:HRH
J*
7r s ;
T;
.20 0
.40
.30
.20 0
.20
.20 0
c: GRH I
J*
Ti
7rSi
.51
.09 0
.21
.09
.20
.18
.09
.03

~

7rEi

7rs

17;

7r s ;

b:ARH
J*

.20
.20
.20

.60
.50
.40

.30
.30
.30

0
0
0

.30
.30
.30

.05
.05
.05

*

*

~

7rEi

7rs

17i

.09
.29
.12

.60
.50
.40

.25
.25
.25

.075
0
0

7rs

17i

.18
.18
.18

.33
.03
0

2.4

Heterogeneity Imbalance

Ti

Ji

7rEi

.25
.15
.05

.30
.20
.10

.60
.50
.40

~

7rEi

.20
.275
.125

.55
.55
.40

d: GRH II
J*
Ti
7rSi
.35
.20 0
.275 .125 .15
.275 .125 0

A second component to heterogeneity, heterogeneity imbalance, is a measure of
the mean difference between subgroup population proportions or between accrual
weights. Let w = (wI' w2 " ' "

Wg )

be the vector of weights for i = 1,2, ... , g subgroups,

then a measure of the information provided by w is the absolute difference in magnitude
between the subgroup weights, denoted the heterogeneity imbalance,

g =2

IWi-Wi·1

/=

(t1W,-W,yt
Cg . 2
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(11)

g 23

-------------------------------

where C, .- is the combination of g pairwise elements.
,~

7

The simplest case is balanced population proportions where I

= O. To distinguish

between population heterogeneity and accrual heterogeneity, fa will be used to denote
accrual heterogeneity. Heterogeneity imbalance will be used as a method to classify the
range of heterogeneity and as a component to increase the sample size in the latter
sections of the paper.

2.5

Clinical trial errors
Trial parameters are constructed such that the trial errors are maximized with

respect to the target errors. Under a frequentist design, the target errors are the Type I
and Type II errors. The errors are composed of four joint probabilities which specify the
complete trial outcome space (Lee and Zelen 2000). The joint probabilities quantify the
probability of the trial outcome, acceptance or rejection of the alternative hypothesis, and
the population truth, the population response rate is greater than or equal to the target
response rate or less than the target response rate,

= p( Reject HI ,lZ' < lZ'1);
P(R+) = p( Reject Hi' lZ' ~ lZ'1 );
P(R-)

subject to,

I I

P( A-) = P ( Accept Hi' lZ' < lZ'j ) ;

P(A+)

= P (Accept Hi' lZ' ~ lZ'j ),

P( ij) =1.

i=(A.R) j=(+.-)

The first joint probability, P(R-) , is the probability of rejecting the alternative
hypothesis and the null hypothesis is true in the population. While the fourth joint
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(12)

probability, P(A+), is the probability of accepting the alternative hypothesis and the null
hypothesis is not true in the population. The frequentist errors, are constructed,

Type I
-

= a = p( Accept HI l;r < lrl ) =

Tvpe II

= fJ = P(Reject H Ilr 2 lr ) =

~

2.6

I

I

P(A-)
P(A-)+P(R-)

(13 )

P(R+)
P(R+)+P(A+)

Trial errors under the subgroup assumption
Under a subgroup assumption the construction of the errors is not as

straightforward as in section 2.5 due to the averaging constraints which allow for a
multiplicity of weight*response profiles,
g

W1t

= ( WI lrl ' W 2 , lr2 ' ... , W g lrg ) ;

L

Wilri

= lr ,

i=1

that sum to a single fixed response rate (Barnes and Rai 2010). The usual assumption, in
homogeneous Phase II trials, is that only a single response exists and given this response
and a set of critical values and sample sizes, the errors can be constructed. Under a
subgroup model, the assumption of the single response still exists, through the mean
response rate, but there exist two levels of additional variation which can result in the
single mean response rate. The first level is the weight profile. The second level is the
actual response profile. Multiple different combinations of weights and response profiles
can lead to a single response rate.
Under a specific single fixed response rate and within each weight profile, there
are weight multiple response profiles that exist which satisfy the main response
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(14)

g

constraint, TCT =

L WiTCTi ;

T = 0, I . Table 2 displays multiple possible weight*response

i~1

profiles that satisfy equation (3), a weighted average, given a 40:60 scheme and ito

= .30.

Table 2: Multiple weight*response profiles satisfying response rate constraint
WI

w2

TCOI

TC02

.40
.40
.40
.40

.60
.60
.60
.60

.73
.55
.31
.24

.01
.13
.29
.34

it=

L WiTCi
.30
.30
.30
.30

To illustrate the added complexity the problem when heterogeneity exists under a
mean of the weight*response profile, we will examine how to construct an error rate
through simulation. Error rates are means, e.g. expected values. For example, under a
binary model, given a response rate, sample size and a critical value, (TC,n,r)
respectively, we can compute the type I error as follows through simulation
h

L I ( x > r ITC = TCo )

Ct=

E[x> rITC=TCo ] =...!..:i-::.!..-I_ _ _ _ __
b

where b is the number of simulations, x is the sum of responses with critical value rand
indicator variable I (.) .

If one chooses to partition the above simulation into, S sub-simulations or partitions
denoted [s], the errors could still be constructed by taking the mean of the sub-simulation
errors since each subgroup simulation is exchangeable,
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(15)

(16)

which is equivalent to

h

.\ I
I

J ( x > r IlZ"

= lZ"o )

-,,=i=,-,---'- - - - -

b

j=i

a = E [ x > r IlZ" = lZ"o] =--'----------'s

(17)

Under latent heterogeneity, the form of the type I error in (17) is not correct since
the partition is not exchangeable. In (16), the composition of the conditioning is exactly
the same across all sub simulations, e.g. exchangeability, a homogeneous condition.
Under a heterogeneity subgroup assumption, and say for explanation, only four
possible weight*response profiles existed to satisfy the averaging constraint, the
conditioning is not exchangeable. Each weight*response profile results in a separate set
of errors, a heterogeneous conditioning. For example, given the first line of table 2,
(.73,.0 l) , a type I and type II error exist. Separate Type I and Type II errors also exist
for each of the remaining weight*response profiles.
Under a subgroup assumption, S is not exchangeable. We assume that the
weights are fixed. Each partition S = s results in a unique partitioning of the complete
space for a fixed weight profile. Under this assumption, (16) becomes

(18)
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where the complete space S is composed of all possible partitions satisfying the
weighted average constraint

(19)

Taking the expectation, under non-exchangeable subgroups, will result in an overall
double expectation that is generally bounded by the target errors. This is not appropriate
under a clinical trial context.
The trial design must guarantee that the error is bounded by the target error for
every non-exchangeable subgroup; the double expectation only guaranteed this on
average. A clinical trial will always be conducted with a specific response profile,
whether known or not known, and the trial design errors must be guaranteed to be
bounded by the target error.
A more appropriate estimate for the errors under heterogeneity where nonexchangeable subgroups exist

.\

a=

..-'-i=--:..I_ _ __

s

where

a(i)

and

fJCi)

/J =

LJ (fJ[iJ > fJ)
....:..i=--'-I_ _ __

s

are the type I and type II errors for each partition, e.g. a specific

weight*response profile satisfying the weighted averaging constraint. The trial errors are
then the mean number of times a partition error crosses the target error boundary over all
possible partitions of the complete fixed weight profile space. If a trial is designed to
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(20)

control the errors in (20), then the trial is guaranteed to control the errors at a specific
level for every weight*response profile as opposed to controlling the errors on average.

22

-----------------------------

-----

CHAPTER 3

LITERATURE REVIEW: EXISTING METHODS FOR HETEROGENEITY

Five methods have been developed to handle response heterogeneity in single arm
Phase II clinical trials. The methods cover both frequentist and Bayesian designs. A
commonality between most methods is the reliance on a known composition structure to
the subgroups; not including the Beta-binomial methodology.

3.1

Unconditional and Conditional Stratified Methods
The methods proposed by London and Chang, unconditional stratified and

conditional stratified methods, account for subgroups with a binary response, similar to a
stratified log-rank test for time-to-event data, under a k-stage design (London and Chang
2005).

Given a known covariate with g subgroups for stages j
let Rm

=I

;~l

= 1,2, ... , m, ... , k ,

I;=l Rij be the sum of responses across all subgroups up to an intermediate

stage m where Rij is the sum of responses for the ith subgroup in the jth stage. The total
sample size across k stages is denoted N

= I~~l I;~l Nij.

Furthermore, let the sampling

weights be proportional to the true population profile, then the general form of the test

statistic for the unconditional stratified method is
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"m ("g (R o ))
Km = -;==============
"m ("X
L.. j=1

L..i=1

L.. J=1

L..I=I

I}

-NIC

N1[o
lj

lj

I

I

(21)

(1-1[0 ))
I

Sample size computation and critical value determination are completed using an
iterative simulation algorithm with set percentages of type I and type II errors spent in
each stage similar in development to the Simon design; see (London and Chang 2005). A
set of stopping boundaries, (( 11' UI), (l2' U2), ... , (Uk)) , where (ll' U1) are the futility and
efficacy boundaries for stage 1 respectively, are constructed to maintain the target type I
and type II errors for the trial. This is in contrast to the Simon design where only a
futility boundary exists. The final result is a sample size and test statistic(s) based on the
estimates for the true population proportions of each subgroup, the sampling weights.

Since the true population proportions of the subgroups are not usually known in
practice, a second form the test statistic was proposed, the conditional stratified method.
The sample size and outcome of the trial are conditioned on the sampling weights, as
opposed to the true proportions, of each subgroup. Conditioning equation (21) on
N J=(!!:!lJ, ... ,(Nim
N J= (nim J' it can be seen that both "m
( Nil
~
nm

"g

L..,=IL..I=1

1

n1[.
I)

01

and the

m

denominator of (21) are constants given

(nil"'" n

im , 1[Oi ).

The sum of responses up to

the immediate stage m is asymptotically equivalent to Km and the rejection region of the
null hypothesis can be expressed as Rm > rm where rm is the critical value of the test
statistic for the mth stage. The general form of the test statistic for the mth stage of the
conditional method is
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P(R

m

=r ) =
m

I

I1 '~ (n'im }
WI

i=l

rlm+·····+rr;m=rm:

r,m (l-Jr .)n",,-r,m

Or

(22)

01

O:;~II/:s;lllm

The final test statistic for k stages is the sum of independent random variables,

In contrast to the unconditional method, many solutions exist to (22) by varying

each of the subgroup sampling weights through (

~: J~ (:: Junder the type I and type

II error constraints. This allows for a wide range of possible accrual scenarios and results
in a similar output as the initial output, before making the selection of the minimax and
optimal solutions, of the Simon designs (Simon 1989).

3.2

Beta-Binomial Method
The third method, the beta-binomial distribution has been previously proposed as

a model that can account for heterogeneity in binary outcome models (Makuch, Stephens
et al. 1989; Yamamoto and Yanagimoto 1994; Hendriks, Teerenstra et al. 2005; Hunt and
Rai 2005; Dragalin and Fedorov 2006; Young-Xu and Chan 2008). For simplicity, we
assume only one stage. To allow for an increase in variation of the response over the
binomial, a subgroup composition is assumed for the responses where response rates are
allowed to vary,

Jri

-

beta( a 0 ,bo ) . Then Ri]

IJri ' has a binomial distribution.

marginal of Rj is a beta-binomial with probability function,
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The

(23)

The mean and variance are
(24)

where

TC

=

a
0
The parameter p is the correlation between the response rates and
a o +bo

quantifies the excess heterogeneity in the response profile above the binomial
distribution. If P = 0 , then the variance of RI degenerates into the binomial variance.
After estimation of the parameters (a o' bo ) , the sample size and test statistics can be
calculated based on the type of difference to be detected (Hendriks, Teerenstra et al.
2005; Chow, Shao et al. 2007). It should be noted that the estimation of the parameters
does not require subgroup source knowledge, prognostic or predictive, about the
heterogeneity; only the estimated amount of variation.

3.3

Bayesian Hierarchical Methods
To implement Phase II designs from the frequentist perspective, a fixed response

rate, whether a single rate or response profile, is specified. Alternatively, a Bayesian
design incorporates a level of uncertainty in the fixed rate by assuming that the response
is random through the use of prior and hyper-prior distributions. A primary design
principle this approach is that the parameters of the response are not independent, but
correlated similar to the beta-binomial distribution (Lee 2009). One such model is the
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Bayesian hierarchical model (BHM) which assumes a hyper-parameter distribution for
the priors, If! , to model the heterogeneity and correlation of the parameters. The joint
distribution of all parameters is constructed by combining the data likelihood, prior and
hyper-prior distributions,

n~, (R~~"., ~ !'(:\"~ IjIl} h~
1

f (R. 1t. 'I' ) = 1(R 11tl p( 1t 1'1'1p( 'I'1= J

1

(25)

likelihooJ

with trial decision making using the posterior distribution,

P( 1t IR)

ff (R,

1t, 'I' )dlf!

= --=-=-----

ffeR,

(26)

1t, 'I')dBdlf!

Due to the intractability and high dimension of the posterior, Monte Carlo Markov Chain
MCMC methods are used to compute the posterior probabilities for each stage of the trial
(Gilks, Richardson et al. 1996).

The fourth heterogeneity method, Bayesian normal-binomial hierarchical model
used in Thall et. ai., is based on the logit model (Collet 2003; Hunt and Rai 2003) and is
constructed such that
iid

Bi =logit(Jri )-N(I1,a

2

)

with 1fI=(I1,a

2

),

11- N(V[,cp[2) and a

2

-

N(v2 ,cp/).

The subgroups are assumed to be exchangeable implying no a priori prognostic
difference in response rates. The heterogeneity is assumed to be predictive.
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(27)

One advantage in using the Bayesian approach is the existence of within subgroup
stopping boundaries allowing for partial subgroup efficacy/futility as opposed to a global
boundary, e.g. Simon or London and Chang methods. As such, a set of identical within
subgroup stopping boundaries, due the exchangeability of the subgroups, are constructed
for each stage of the trial. Once all the patients in subgroup i are evaluated, futility and
efficacy stopping boundaries are applied for this subgroup,

(28)

and
P(tru > trOi Idata) ~

Lt,

using the data from all subgroups to determine if a particular subgroup portion of the trial
should be stopped or continue accrual until the next decision point using an appropriately
small value for I and a large value for u. The values for the boundaries are usually
chosen to give good operating characteristics when compared to a frequentist design.
Each subgroup has an identical stopping boundary similar to running multiple
simultaneous trials with the conditioning allowing the sharing of information across
subgroups and minimization of resources by using the data from all subgroups to
determine individual subgroup outcomes.
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(29)

3.4

Bayesian ANCOV A Method
The fifth method, Bayesian normal-binomial regression model or BANCOV A

model, was proposed by Wathen and Thall (2008). To compare the model with the
earlier heterogeneity notation of (6), the model was reparameterized. The model,
fa gil ( reT g ((J) ) = ~ +

is constructed with 771

I

;=1 {77i + r/ (T = I)} I (G = g) ,

= 0 for interpretational convenience. It should be noted that the

ranges of the parameters are not consistent between the heterogeneity model (6) and the
model (30) which the models mean response rate on the logit scale. Model (30) has no
assumption on the structure of the variance as in model (27), where
~

iid

=10gil ( re;) ~ N (f-L, (Y2)

is assumed, modeling the mean response as opposed to both

the mean and variance of the response.

The prognostic effect of subgroup g compared with the baseline subgroup, e.g.
subgroup 1, is 'lg and the predictive effect for subgroup g is T g . To construct the hyperparameters for each of the priors, Wathen and Thall developed an algorithm assuming
small variances for historical priors and large variances for experimental priors by
equating the moments of a beta distribution to a normal distribution. For the complete
hyperparameter algorithm and the logic for their assumptions, see (Wathen, Thall et al.
2008).

Once the priors have been computed, the posteriors are constructed using MCMC
methods. Subgroup-specific stopping boundaries are then constructed similar to (28) and
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(30)

(29) where the subgroup specific stopping boundaries (I;, uj ) are subgroup dependent on
the prognostic effect as opposed to the BHM model where the boundaries are identical.
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CHAPTER 4

AN ADAPTIVE PHASE II DESIGN TO ACCOMMODATE HETEROGENEITY
We present a method to account for latent heterogeneity under the Simon design
context which adapts the second stage sample size and critical value of a Simon design
based on the outcome of the first stage under the presence of a heterogeneity statistic.
The adaptive design denoted the 2-stage heterogeneity adaptive design (2HA) preserves
the operating characteristics of the Simon trial under no heterogeneity, e.g. no change to
the design, and preserves the first stage operating characteristics, moderate probability of
early termination. For simplicity and due to the relatively small sample sizes in Phase II
trials, detecting only two groups is attempted.
The basic algorithm is as follows, compute the Simon design parameters given a
weighted average response rate, which asymptotically e.g. n --7

00 ,

mirrors the population

response and conduct the first stage of the trial. After the first stage and the first stage
criterion was met, x> 'i ' determine if subgroups exists through a classification algorithm.
If the trial fails to meet the first stage critical value, the trial has failed. The etiology of

the failure is unknown; either the trial design failed due to latent heterogeneity or the
probability that the response meets or exceeds the clinically relevant response is minimal.
Under this scenario, no change to the second stage will result in a successful trial and will
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not be considered as relevant to the design at this point. The design focuses only on trials
that have met the first stage criterion.
Once the subgroups are identified, the subgroups are tested for the presence of
heterogeneity. If no heterogeneity is detected, enroll the remaining patients per the
Simon sample size parameters and complete the trial using the Simon critical value. If
heterogeneity is detected using a liberal test, the overall sample size will be increased,
with the additional sample size for the first stage included in the new second stage sample
size, using an empirically derived inflation factor. A new critical value will be
constructed given the new second stage sample size and that the trial has succeeded into
the second stage.
The Beta-Binomial posterior predictive distribution is used as the model
distribution to determine new parameters under heterogeneity. Enroll the additional
patients and test the global hypothesis with the new critical value. This new design will
control the errors bounded at the target errors given knowledge on the average response,
!"Co and !"C],

4.1

the number subgroups expected, g

= 2.

Subgroup identification
This design relies on the ability of a classifier to find the true subgroups in the

sample. Multiple methods exist for finding subgroups in supervised and unsupervised
manners. A supervised classifier is one in which the true identity of the object being
classified is known. For example, supervised classification can be conducted on age or
gender. In both instances, the true state is known. Unsupervised classifiers are ones in
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which the true state is not known and is estimated through patterns in the data. An
example may be a set of unknown biomarkers. The true state of the unknown biomarkers
is generally not known. Patients are grouped into subgroups based on the expression
patterns of these biomarkers.
The study of supervised classifiers is a broad subject with many classifiers that
fall under this category. Some examples are recursive algorithms such as random forests,
machine learning algorithms such as support vector machines or statistical classifiers
such as linear discriminate analysis or principal component analysis.
The most popular method for unsupervised learning is clustering algorithms.
Clustering is the assignment of samples into subsets based on a distance or dissimilarity
measure which measures the distance between samples based on the data (Datta 2006).
Multiple types of clustering exist such as agglomerative methods, and k-means. See
Romesburg for an exhaustive summary of the multiple methods that exist (Romesburg
2004).
For the purposes of this paper, the classifier is assumed to have 100% accuracy.
This is to remove any variation that might be caused by the actual classifier. In the case
of unsupervised classifiers, there may be a level of error associated with either the
classification method based on a small sample size as is the case in Phase II trial first
stages or error associated with the measurement platform such us the case with high
through-put micro array platforms.
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The classifiers for these reasons will be assumed to be built using supervised
variables, say age and gender. In this case, the classifier will always have 100%
classification accuracy. The utilization of non- perfect classifiers in the algorithm is a
subject for future work.

4.2

Testing for heterogeneity
Multiple methods exist for testing the assumption of heterogeneity or

overdispersion in binomial data under a grouped data assumption. The preferred method
is to test for lack of fit of the data to the binomial model with parameter

Jr (Collet

2003).

We focus on global goodness-of-fit methods where the test statistic evaluates the
unspecific hypothesis, model fits versus model does not fit.

The two most common test statistics are the Pearson and Deviance test statistics,

(31 )

and

(32)

respectively (Kuss 2002). As the number of groups increases, g
statistics should be approximately equal, X 2

"'"

---7

00 ,

the two test

D. Under the context of this problem,

two groups and only one sample of each group, there is lack of data, known as sparcity,
which results in X 2

-:j:.

D. The sparcity is due to the fact that only one example of the
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data exists during a single trial, e.g. n = 1. It has been shown that for n ::; 5 , the Pearson
test is too conservative and the Deviance test is erratically anticonservative (Kuss 2002).
This undermines the use of either statistic as a robust method of determining
heterogeneity.
A third method is to use a modified Pearson test statistic where the Pearson
statistic family is generalized by adding an additive constant to X2 first described by
Farrington,

(33)

The standardized test statistic is then compared to a standard normal distribution
(Farrington 1996). This method has been shown to be more stable than either the
deviance or standard Pearson statistics under sparcity (Kuss 2002).
Due to the sparcity of the data, heterogeneity is determined using a liberal p-value
threshold, p::; .30. The motivation for using a liberal p-value threshold is that it is
advantageous to err on the heterogeneity side. If heterogeneity truly does exist and the
test determines no heterogeneity, the Simon trial parameters are not a good fit to the data.
The reverse, the test determines heterogeneity when heterogeneity does not exist, will
result in the use of the Beta-Binomial which will still provide an adequate fit to the data.
In simulation, the Farrington test had a power to detect heterogeneity above
80%. The type I error is inflated, -30%, which is allowable since the model distribution
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will still fit and will result in a only modest increase in sample size. This is shown in the
results section.

4.3

Variance inflation factor
To increase the sample size in the second stage to account for the response

heterogeneity requires estimation of a variance inflation factor (VIP). The standard
interpretation of the VIP is as an unknown scale parameter which relates the variance of a
Binomial random variable to the variance of an overdispersed Binomial random variable,
a Beta-Binomial random variable, section 4.3.1. This interpretation, under a two stage
trial, will not result in a robust estimate since it relies on estimation of the VIP through a
Pearson or Pearson type statistic.
A second interpretation for the VIP is the inflation factor necessary to increase the
sample size to account for heterogeneity, section 4.3.2. Empirical results are used to
construct this definition. This method will result in a robust method that leads to a
sample size that will control the trial errors at the target errors.

4.3.1

Estimation of theoretical VIF
Given the following model,

(34)

for i =1,2, ... ,g , we can compute the variance of the observed responses, Xi'
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v (Xi) = E[ n/ri (1- Jri )] + V(niJr i)
=ni ( E [Jri ] -

E [ Jri 2 ]) + ni2rpJri ( 1- Jri )

=ni ( Jri -rpJri ( 1- Jri ) -

=niJri ( 1Under the special case

Tl i

=n for all

Jri

) [

Jri 2 )

(35)

2

+ ni rpJri ( 1- Jri )

1+ ( ni - 1) rp ]

i,

V ( Xi)

= TlJri (1 - Jri ) [ 1+ ( n - 1) rpJ '

(36)

'------y-----'

,,2

such that

(52

is denoted the heterogeneity factor and rp is denoted the VIF. Since,

E [X 2 ]

""

g [ 1+ ( Tl -1) rpJ

= g (52,

(37)

it follows that
~
6"2 -1
rp=-

n-]

Equation (36) provides the standard interpretation of the VIP and estimation through
equations (37) and (38). Under the special case of a two stage trial, where only a single
sample is used, the stage one results, the estimation of the VIF through (38) will not be
robust due to sparcity.

The use of the Farrington X 2 to replace the standard X 2 was allowed in section
4.2 for the heterogeneity test statistic since it is advantageous to err on the side of
heterogeneity. The only error which must be controlled absolutely is the Type II error;
allowing for the type I error to be exceeded. This is not an acceptable solution in the
37

(38)

estimation of the VIF. The VIF is directly correlated with the resulting sample size of the
trial. In tum, the sample size is directly correlated with the trial errors. Allowing for
inadequate control of the errors in the estimation of the VIF will result in adequate
control of the trial errors.

4.3.2

Estimation of empirical VIF
A second logical approach to estimate the VIF is through the trial conduct. The

increase in variation can be attributed to two components not present under a
homogeneous population, the weight profile and the response profile. Under a
homogeneous population, the response profile is a single response. The second
interpretation of the VIF is as the minimum amount necessary to increase the sample size
to account for heterogeneity.
Given the first stage results and the presence of heterogeneity, an estimate for the
heterogeneity imbalance, j can be estimated through (11). The absolute magnitude of
difference in the response profile can be estimated

(39)
where

itli

=~

is the estimate of the response in the ith subgroup with response

Xi

and

nli

2

sample size n 1i such that

LXi
i=l

2

= X and

L

n1i

= n1 .

Equation (11) provides information on

i=l

the weight profile while equation (39) provides information on the response profile
beyond the information provided by a fixed homogeneous response rate. For simplicity,
the number of subgroups is 2.
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A natural estimate for the VIP for a single trial is the product of the estimate of
the heterogeneity imbalance and the response rate imbalance,

(40)

A new sample size to account for heterogeneity can be constructed

(41)

where n is the original Simon total sample size. When the heterogeneity imbalance is
non-existent, j = O. Small differences in the response profile lead to a small VIP. As
either the difference in weight profile diverges or the difference in the response profile
diverges, the sample size will increase.

4.4

Model Distribution
Once heterogeneity has been detected through subgroup identification, the trial no

longer adheres to the assumption of a Binomial distribution. As such, the Binomial trial
parameters and model are no longer valid. Two factors will determine the new model
distribution, the structure of the trial and the structure of the data.

4.4.1

Predictive posterior Beta-Binomial
The structure of the trial is a two-stage process and this process should be

inherently modeled in the model distribution for parameter construction. The data is
structured such that

Xi

~ P (Xi

I"i ) ~ Bin ( ni ' "i );
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i = 1, 2, ... , g

(42)

and

(43)

where X is the sum of responses in the first stage of the data. This two-stage process and
the extra-binomial variation due to (42) and (43) can be explicitly modeled using the
posterior predictive Beta-Binomial distribution.
The posterior predictive distribution (PP) quantifies the probability of a future
observation of the data, y, out of m samples given some data has already been observed,

x, out of n samples,

(44)

In the case of a two-stage trial, the PP distribution quantifies the distribution of the stage

two outcome given the stage one outcome. In addition, by treating the parameter

JZ" as

random, as opposed to a fixed as in the binomial distribution, the variance of X is larger
than a strictly single parameter binomial model for X .
For completeness, the composition of the Beta-binomial is repeated, removing
subgroup notation for simplicity,

p(JZ") - Beta(ao,bo); p(xlJZ") - Bin(n,JZ");
P ( JZ" I x) - Beta ( JZ"; ao + x, bo + n - x) ,
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(45)

------------------------------------------------------------

where Beta ( x; a, b) =

I ( ),,-1 (1qJ

h-I

qJ)

d qJ. The first distribution in (45) is the prior

distribution of the response parameter Jr. The second distribution is the data likelihood
which satisfies the data structure in (42). Combining the data prior with the data
likelihood results in the posterior distribution p (Jr Ix). Heuristically, one can interpret
the posterior distribution, p (Jr Ix) , as an assumption distribution, p (Jr) , updated with
actual data from the trial, p ( x IJr)

.

Then, it can be easily seen that the PP distribution is Beta-binomial through the
conjugateness of the Beta distribution and Binomial distribution,

p(ylx)= fp(y,Jrlx)dJr
= fp(YIJr)p(Jrlx)dJr
"'" Bin(n-ni'Jr)Beta(Jr;ao +x,bo +nl-x)
= Beta (ao,bo ) -lBeta( Jr;a o + y,bo + (11- nl ) - y)
where Beta ( au' bo ) = r (ao ) r (bl)) / r (ao + bo ). The extra-binomial variation or
heterogeneity is modeled through the data prior (See (24».

4.4.2

Prior specification
The standard practice in prior specification is to specify a non-informative prior.

A non-informative prior will minimize the impact of a subsequently misspecified prior on
the overall posterior distribution (Lee 2009). Non-informative priors are priors with large
variance. The standard method to parameterize a non-informative Beta prior is to base
the prior on a small sample size such as

11

= {I, 1/2,2} (Thall, Wathen et al. 2003). For
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(46)

------------------------------

-------------

example, basing a beta prior with Jt =.30 and n =1 will result in the parameterization of
a o = .30 and bo = .70 since

(47)

As the sample size that the prior is based upon increases, the variance of the random
response rate shrinks towards zero as seen in table 4.
Table 3 Mean and variance for different prior specifications by sample size

n

(ao,bo)

1r

1

(.3,.7)

.30 .105

10

(3,7)

.30 .033

100

(30,70)

.30 <.01

V(1r)

The prior for our model will be based on the null response given a sample size of
n = 1 which will result in the parameterization given in (47).

4.2.3

Beta-Binomial predictive posterior error construction
The structure of the errors in section 2.5 can be used to develop the errors for trial

design using the Beta-Binomial PP distribution (Barnes and Rai 2010). The joint
probability of outcome and truth in a k-stage trial is composed of (k+ 1) subspaces, k stage
outcomes and the population truth. For a two stage design, the joint probabilities are
specified as follows,

P ( outcome, truth) = P ( outcome stage 1, outcome stage 2, truth).
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(48)

The joint probabilities are specified using the conditional probabilities and marginal
probabilities of the (k+ 1) components through Bayes theorem.

P(A-)

= P( Jr < Jrl ,Accept HI)
= P ( Jr < Jrl' X > 'I ' x + Y > r)
= P ( Jr < Jr1 Ix > 'I, x + Y > r) P ( x + y > r Ix > 'I ) P ( x > 'I )
III

=I

n-fl t

I

p(Jr<Jrlly=j,x=i)P(y=jlx=i)P(x=i)

i=r,+1 j=r+l-i

The joint probabilities that include an accept outcome are intuitive. This is not the case
for the joint probabilities which include a reject outcome.
Under a two stage design, if the first stage criterion is not met, then the trial stops
without proceeding stage two. To specify the joint probabilities under rejection, it is
necessary to include the conditional probability of the second stage criterion not being
met given the first stage criterion is not met; a situation which is impossible in actual trial
conduct. This specification is not intuitive, but necessary to assure that the total outcome
space is complete.
The probability of rejecting the alternative hypothesis and the null hypothesis is
true is the sum of the product of the conditional probability that the null hypothesis is true
given the first stage criteria is not met, the conditional probability that the second stage
criteria is not met given that the first stage criteria is not met, and the marginal
probability that the first stage criteria is not met and the product of the conditional
probability that the null hypothesis is true given the trial is successful, the conditional
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(49)

probability that the second stage criteria was met given the first stage criteria was met,
and the marginal probability that the first stage criteria was met,

P( R-)

= P(ff < ffl ,Reject HI)
= P ( ff < ffl ' X S Ij , x + Y S r) + P ( ff < ffl ' X > Ij x + y S r)
= P ( ff < ffl Ix S Ij ) P ( x + Y sri x S Ij ) P ( x S Ij ) +
P ( ff < ffl I x + y > r, x > Ij ) P ( x + y > r Ix > Ij ) P ( x > Ij )
'i

=I

(50)

r-i

I

P ( ff < ffl I y

= j, x = i) P ( y = j I x = i) P ( x = i) +

P ( ff < ffl I y

= j, x = i) P ( y = j Ix = i) P ( x = i).

i=O j=O

n1

r-i

I I

i=r,+1 j=O

The remaining two joint probabilities are similarly found replacing ff < ffl with
ff?:

ffl .

Once all four joint probabilities are constructed, the errors in section 2.5 (13) can

be constructed. The chosen set of parameters is the set of parameters satisfying the error
constraints and resulting in the optimal solution as with Simon's design.

4.5

Two stage Adaptive Heterogeneity trial algorithm
Combining the theory in the previous sections, an algorithm for the 2HA design is

constructed which determines the trial outcome. For simplicity, the number of subgroups
to be detected is two. The algorithm is as follows:
1. Compute Simon parameters given a null response rate, ffo' treatment effect,

and target errors,

Ct,

fJ

resulting in parameters

0,

Ij, nl ,r, n

2. Conduct first stage of trial using Simon parameters resulting in the number of
successes, observed value x
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3. Determine if a classifier exists to partition the first stage sample into two groups.
Test for heterogeneity using the Farrington test,

If a classifier does not exist, proceed to step 6.
4. Calculate a new maximum sample size, n *, given the observed heterogeneity
imbalance and observed absolute difference in response profile, n* = n ( 1+ i
5. Calculate a new critical value, r* I(X

Iffll) .

= 'i,n *), using the Beta-Binomial PP

distribution given that the first stage criterion was met for n * under the target
errors.
6. Conduct the second stage under the appropriate sample size. If no heterogeneity
exists (r, n) ; if heterogeneity exits, (r*, n *) resulting in observed value y
7. Compare x + y to r under no heterogeneity and to r * under heterogeneity. If
x + y > r or x + Y > r * , then the trial is estimated to be a success.

4.6

Estimation of response rate
It has been shown that under multiple stage designs, e.g. sequential tests, the

maximum likelihood estimator (MLE) is generally biased (Li and Li 2000; lung and Kim
2004). Since only extreme cases are observed in a 2-stage Phase II trial, e.g. crossing a
futility boundary in stage 1 or crossing an efficacy boundary in stage 2, an optional
sampling effect is introduced biasing the MLE (Whitehead 1986). The optional sampling
effect causes the variance of the estimate to increase thus increasing the bias. The bias is
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most pronounced in trials with only a futility boundary in stage 1, as compared to both a
futility and efficacy boundaries, which is the case with both the Simon and 2HA designs.
lung and Kim have shown that in a two stage trial the statistic
iV/ denotes the stage the trial terminates, M

={I, 2} , and

(M, S) , where

S denotes the total number of

responses accumulated up to and including stage M , is a complete and sufficient statistic
for

1l",

the response rate of the trial.
Then, since itj

sufficient statistic

=

Xj /

nj is an unbiased estimator of Jr IM

= 1 and the complete and

(M, S) , the uniformly minimum variance unbiased estimator

(UMVUE) of 1l"can be constructed by the Rao-Blackwell theorem (Blackwell 1947),

(51)

which will not ,by definition, suffer from the bias of the MLE in a sequential test. The
UMVUE for

1l",

given a two stage trial is then

(52)

where (nj' n - nj ) are the first and second stage sample sizes and 'l is the first stage
futility boundary (lung and Kim 2004).
As an example, say that the following responses were observed at the end of the
second stage of a trial (m, s) =(2,7) with trial parameters ('l, nj , r, n) =(3,13,12,33). The
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support space, e.g. the summation space, is constructed for the UMVUE,
(~

+ 1) u ( s - n + n l ) = (3 + 1) u (7 - 30) = 4 and s ( j (nl -1) = 7 ( j (14 -1) = 7 resulting in

~
7

A

JrUIHVUE

I(

m = 2, s = 7

)

=

[13-1J[ 30 J
i-I
7-i

1=
I (J(
~I
7

30.

i=..j

1

(53)

.322

S-l

In contrast, the MLE is itMLE = ~ = .212 which is heavily downward biased.
33
Using these results and the composition of the source of the heterogeneity,
estimable and identifiable subgroups, a general form of the UMVUE can be constructed.
Given the sum of responses in stage one and stage two follows a Binomial distribution,
( Xi

+ ~) IJri

-

Bin ( ni , Jri ) for each subgroup, the UMVUE of the response rate

Jr

is the

weighted sum of the UMVUEs for each individual subgroup,

(54)

where nl g is the sample size for subgroup g in the first stage, n,8 is the total sample size
for subgroup g and

/jg

= wg/j is the weighted first stage critical value for the gth

subgroup. A weak. assumption of independence is assumed and the assumption that the
observed subgroups weights approximate the true population weights as n ~ 00 •
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CHAPTERS
EFFECTS OF HETEROGENEITY ON PHASE II TRIALS: RESULTS

5.1

Effects of heterogeneity on Simon trial designs
For simplicity, the number of subgroups in the simulations was chosen to

be g

= 2. Given a combination of weight and response profile, the type I and type II

errors were computed using Bl

= 10,000 Monte Carlo iterations.

Due to the multiplicity

of combinations of response/population profiles with a common mean response and to
allow

7[Ti

where

7[Ti

> 7[Ti' for i =f. i' to be uniformly distributed across the g subgroups,

(B2 I g = 2) = 40,000 Monte Carlo iterations were conducted; for example,
(B2 I g = 2) = 4 and

7[s

= .25

using a simple average can result in

,
)_f(.1,.9,.30,.20) (.1,.9,.40,.IO)}
( W 1 ,H'2,7[OI,7[02 -l(
)
l.I,.9,.20,.30

5.1.1

(.1,.9,.10,.40)

Simulation parameters

A sample of population proportion profiles were chosen to cover a heterogeneity
imbalance of j

= (0,.98) for the two subgroup simulations and was simulated as follows:

1. Under HRH or ARH, given the population profile for a imbalance I , the first

(g -1) historical response rates,

7[Oi'

were randomly generated from a uniform
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(55)

---------------~-------~~---

distribution,

lCOI ' lC02 "

---- - - - - - - - - - - - - - -

------ - - - - - - - - - - - - - - - - - - - - - - - - - -

.. ,lCOI g-I) ~ U ( 0, ltO + 8*) where (lts' 8*) are specified, for

example (lts' 8* ) = (.25, .15). The parameters for the uniform distribution are
problem specific and are to subject to the constraints 0::; lCOi

::;

I for all i. The

gth null response rate was generated to satisfy the averaging method. The

alternative response rate was constructed in a similar fashion for the HRH and
ARH classes. Under GRH, the odds ratio of each subgroup was constrained to
equal the odds ratio for the Simon design such that,

solving for

lCli

given

lCOi '

Then, 8,.

= lCli -lCOi •

2. If accrual is allowed to diverge from the population profile, an accrual profile is
constructed for each subgroup to replace the population profile,

first (g -1) subgroups at

(Wi ± da) .

3. Given a population or accrual profile and a response profile, simulate multinomial
random variables nll , n21 , ••• , n~ I with fixed sample size nl and cell
probabilities 1fT

= (lCTi ' lCn

' ... , lCT Ii

) •

4. For values of ( Nil' N 21"" ,Ng1) = ( n ll , n 2 1"'" ng 1) , simulate binomial random
variables

X Ti

with sample size nil and response rate
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lCri ·

Then xT

= I~=l X Ti

is

compared to the critical value

fj

derived from the Simon trial design using the

target mean response rates and nominal errors. If xT

~ fj ,

then the trial is stopped

for futility.

5. If x T > fj , repeat steps (3-4) for the second stage, 112 to determine y ; otherwise
hI
XT

= O.

Compare x T + h to the critical value r from the Simon trial design. If

+ YT > r , then the null response rate is rejected.

6. Repeat steps (2-5) for B1

= 10 000 simulations and

T = (0,1). Then,

(I:~I I (xo + Yo > r) / B) I1[ = 1[0 is the type I error of the test and
(I:~I I (XI + YI :::;; r) / B) I1[ = 1[1
7.

is the type II error of the test.

Repeat steps (1-6) for B2 combinations of response and population profiles.
Construct the actual type I and type II errors using equation (20).

5.1.2

Results
The first simulation compared the effect of varying levels of heterogeneity

imbalance using simple averages for a 2 subgroup trial (Barnes and Rai 2010). The data
was simulated using R.9.2 (Team 2005). The target type I and type II errors are

(a, 13) = (.10,.20). Table 5 displays the errors with corresponding 95% quantile intervals
for each class of heterogeneity. Under all three classes of heterogeneity and a
heterogeneity imbalance of I :::;; .20, the actual mean errors approximate the target errors.
When the imbalance increases, I > .20 under HRH and GRH, the actual mean errors
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-------------------------------------------------

exceed the target errors with increasing divergence as the imbalance increases. Under
ARH, the type I mean error approximates the target error with the type II following a
similar, but less extreme divergence pattern as HRH and GRH. As the imbalance
increases, the ranges of error estimates increase with the exception of the ARH type I
estimates which maintain a constant quantile interval irrespective of the imbalance. The
effect of heterogeneity is most pronounced on the type I error range under HRH and more
pronounced on the actual type II error range under GRH. Under an unknown response
profile for 2 subgroups, the mean probability that trial is moderately to extremely
oversized is 22%,
42%,

1& - al ~ .04, and the mean probability that the trial is underpowered is

1;1 - pi ~ .04 .
To further identify the effect of heterogeneity, tables 6 and 7 display the

probability distributions for the oversizing or underpowering of the trial. Under HRH
and GRH, as the heterogeneity imbalance increases, the mass of the error estimate
distributions location shift increasing farther to the left resulting in larger divergences
from the nominal errors. This results in strong negative effects of heterogeneity on the
trial operating characteristics. For example, for I

= .20

under HRH, the majority of

oversized trials are in the range of (.10, .12] , a small divergence from the nominal errors.
When 1=.40 and 1= .80, the majority of oversized trials are in the ranges of (.2,.3] and
(.4,1] respectively, substantial divergences from the target error and of high concern to
the trial conduct; a similar pattern in seen with the actual type II errors. The exception is
the oversized trials under ARH. Irrespective of the heterogeneity imbalance, the majority
of oversized trials are only slightly oversized in the range of (.10, .12]. This would imply
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that even though the trials are oversized, the effect of the heterogeneity is minimal on the
type I error.
Table 4: Size and power for each class of heterogeneity by heterogeneity imbalance with
corresponding 95% quantile and Monte Carlo intervals for a 2 subgroup example
Actual
Error I
Class I
HRH .02
.10
.20
.11
.13
.40
.60
.16
.80
.20
.98
.23
ARH .02
.10
.20
.10
.40
.10
.60
.10
.80
.10
.98
.10
GRH .02
.10
.20
.11
.40
.13
.60
.16
.80
.20
.98
.23

95%
QI
(.08, .11)
(.04, .20)
(.01, .34)
(0, .50)
(0, .65)
(0, .76)
(.09, .11)
(.09, .11)
(.09, .11)
(.09, .11)
(.09, .11)
(.09, .11)
(.08, .11)
(.04, .20)
(.01, .34)
(0, .50)
(0, .65)
(0, .76)
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Actual
Error II
.20
.21
.22
.25
.28
.31
.20
.20
.21
.22
.23
.24
.23
.24
.26
.30
.33
.36

95%
QI
(.18, .22)
(.11, .32)
(.06, .46)
(.03, .61)
(.02, .76)
(.01, .86)
(.18, .22)
(.14, .28)
(.09, .37)
(.06, .47)
(.04, .58)
(.03, .67)
(.19, .30)
(.14, .46)
(.07, .66)
(.03, .83)
(.01, .94)
(0, .98)

Table 5 Distribution of actual type I error for each class of heterogeneity and
heterogeneity imbalance for a 2 subgroup example.

Class
HRH

ARH

GRH

I
.02
.20
.40
.60
.80
.98
.02
.20
.40
.60
.80
.98
.02
.20
.40
.60

.80
.98

(aMe

-

.31
.09
.05
.03
.02
.01
.26
.26
.26
.26
.26
.26
.31
.09
.05
.03
.02
.01

.12]

Distribution of Actual Type I Error
(.12-.14] (.14-.18] (.18-.2] (.2-.3]
.01
.10
.05
.03
.03
.03
0
0
0
0
0
0
.01
.10
.05
.03
.03
.03

0
.17
.09
.06
.04
.04
0
0
0
0
0
0
0
.17
.09
.06
.04
.04
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0
.08
.04
.03
.02
.01
0
0
0
0
0
0
0
.08
.04
.03
.02
.01

0
.04
.17
.12
.09
.08
0
0
0
0
0
0
0
.03
.17
.12
.09
.08

(.3-.4]

>.4

0
0
.09
.12
.07
.06
0
0
0
0
0
0
0
0
.09
.10
.08

0
0
0
.12
.22
.27
0
0
0
0
0
0
0
0
0
.12
.22

.06

.27

Table 6 Distribution of actual type II error for each class of heterogeneity and
heterogeneity imbalance for a 2 subgroup example

Class I
HRH .02
.20
.40
.60
.80
.98
ARH .02
.20
.40
.60
.80
.98
GRH .02
.20
.40
.60
.80
.98

(fJMC -.22]

.36
.08
.04
.03
.03
.01
.37
.18
.10
.06
.04
.03
.29
.06
.04
.03
.02
.01

Distribution of Actual Type II Error
(.22 - .24] (.24-.28] (.28 - .3] (.3-.4]
.02
.09
.05
.03
.03
.02
.01
.15
.09
.07
.06
.05
.21
.07
.02
.02
.03
.02

0
.16
.08
.06
.04
.03
0
.12
.14
.12
.08
.07
.19
.07
.07
.03
.01
.01

0
.07
.04
.03
.02
.01
0
.01
.05
.05
.05
.02
.06
.05
.01
.03
.02
.01

0
.08
.17
.11
.08
.07
0
.01
.lO

.13
.13
.13
.03
.14
.11
.07
.08
.07

(.4 - .5]

>.5

0
0
.12
.10
.08
.07
0
0
.01
.05
.08
.09
0
.10
.08
.07
.05

0
0
.12
.25
.31
.35
0
0

.24
.32
.35

.03

.38

.lO

.06
.13
.18
0
.lO

The second scenario is the weighted average, table 7. Under HRH and ARH, the
actual mean errors maintain the target errors with the quantile confidence intervals only
slightly larger than the Monte Carlo error bounds. The mass of the actual error
distributions are in the range of (.10, .12] and (.20, .22] respectively, a divergence between
target and actual errors implying that some trials do not meet the error targets. Under
weighted averages, the effect of heterogeneity is minimal, but not absent, on the
operating characteristics of the Simon trial.

54

Table 7 Errors for each class of heterogeneity by heterogeneity imbalance with
corresponding 95% quantile for a 2 subgroup example using weighted averaging.

Class
HRH

ARH

GRH

I

.02
.20
.40
.60
.80
.98
.02
.20
.40
.60
.80
.98
.02
.20
.40
.60
.80
.98

Actual
Error I

.10
.10
.10
.10

.10
.10
.10
.10
.10
.10
.10
.10

.10
.10
.10
.10

.10
.10

95%
QI
(.09, .11)
(.09, .11)
(.08, .12)
(.08, .12)
(.08, .12)
(.09, .12)
(.09, .11)
(.09, .11)
(.09, .11)
(.09, .11)
(.09,.11)
(.09. 11)
(.09, .12)
(.09, .12)
(.08, .12)
(.08, .12)
(.08, .12)
(.09, .12)

Actual
Error II
.20
.20
.20
.20
.20
.20
.20
.20
.20
.20
.20
.20
.20
.20
.21
.22
.22
.23

95%
QI
(.18, .22)
(.18, .22)
(.18,.22)
(.18, .22)
(.18, .22)
(.18, .22)
(.18, .22)
(.18, .22)
(.18, .22)
(.18, .22)
(.18,.22)
(.18, .22)
(.18, .24)
(.18, .24)
(.18, .24)
(.18, .25)
(.18, .25)
(.18, .24)

To allow for the uncertainty in either the true proportions or the accrual, two
levels of error were introduced during patient accrual, da

= .05.

The accrual

heterogeneity imbalance was allowed to vary between 0 and 5% of the population
heterogeneity imbalance. The accrual difference can be attributable to accrual divergence
or error in proportion estimation. Table 8 shows the results for g

= 2 subgroups with an

accrual divergence parameter of 5 %. The actual mean errors approximated the target
errors in almost every case with the exception being under GRH actual type II errors.
The reason for this divergence is unknown at this time. The distributions of the errors are
more dispersed than the weighted average method due to the variation in accrual which
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leads to more specific combinations of a weight and response profile being underpowered
or oversized.. The strength the errors is increased when comparing the error estimate
distributions between weighted averages and weighted averages with accrual divergence.
Table 8 Simon Optimal design with s=2 subgroups population using weighted average
= .05.
with accrual differences,

aa

aa
HRH

ARH

GRH

1

.10 .02
.20
.40
.60
.80
.10 .02
.20
.40
.60
.80
.10 .02
.20
.40
.60
.80

Actual
Error I

.10
.10
.10

.10
.10
.10

.10
.10
.10
.10
.10

.10
.10
.10

.10

95%
Actual
CI
Error II
(.07, .14)
.20
(.07, .13)
.20
(.08, .14)
.20
(.07, .12)
.20
(.08, .13)
.20
(.09, .11)
.20
(.09, .11)
.20
(.09, .11)
.20
(.09, .11)
.20
(.09, .11)
.20
(.07, .14)
.20
(.07, .13)
.21
(.07, .12)
.22
(.07, .12)
.22
(.08, .13)
.23

5.2

Effects of heterogeneity on Adaptive trial design

5.2.1

Simulation parameters

95%
CI
(.16, .24)
(.16, .24)
(.16, .24)
(.16, .24)
(.16, .24)
(.17, .23)
(.17,.23)
(.17, .23)
(.17, .23)
(.17,.23)
(.16, .26)
(.17, .26)
(.17,.38)
(.17,.29)
(.17, .34)

The data for the 2HA simulation was simulated in a similar manner as with the
Simon simulation in section 5.1.1. Only two groups under GRH were simulated with the
weighted average constraint. Under latent heterogeneity, GRH is the most appropriate
class of heterogeneity. It is also assumed that if a response rate was hypothesized, that
the rate was hypothesized from data that follows the population as a whole. For example,
if a trial response rate of .30 is hypothesized, then the population in general follows a
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mean response of .30. No subgroups are known prior to trial conduct, though this does
not occlude the existence of said subgroup, and a Treatment x Marker interaction is not
known. For each weight scheme of the weighting profiles, 10,000 simulations were
conducted. The actual errors, the percentage not meeting the target errors, are reported.

5.2.2

Simulation Algorithm
The data was simulated using a Linux cluster by parallelizing the simulation using

R.9.2 (Team 2005). The data and trial conduct is simulated as follows

1. Given a null response rate and alternative response rate with a specified weighting
scheme,

1Co' 1CI ' ( WI' w 2 )

,

and target errors,

(a, [3) construct the Simon trial

parameters and a null and alternative response profile by weighted averages
satisfying the odds ratio criterion.
2. Given a weight profile and an alternative response profile, simulate multinomial
random variables nil' n21 with fixed sample size n l and cell probabilities

3. For values of (Nil' N 21 )
sample size

nil

critical value

1)

= (nil' n21 )

,

simulate binomial random variables

and response rate

1Cli

•

Then

X

= I~=I Xli

derived from the Simon trial design. If

stopped for futility.
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Xi

with

is compared to the
X ~ 1) ,

then the trial is

4. If X>

fj

then determine if heterogeneity is present using the Farrington X 2 statistic

and a liberal p-value, p;:::: .30.

5. Compute the heterogeneity imbalance and absolute magnitude in difference in
responses. Then constmct a new sample size, n * using (41).
6. Repeat steps 2-5 for B=50,000 iterations.
7. Given the unique possible new sample sizes in the 50,000 iterations, constmct
new critical values, r * , given

fj

out of n1 responses in the first stage and for

each of the new sample sizes using the predictive posterior Beta-Binomial
distribution.

8. If

p;:::: .30 , then n2 = n * -n1 and r

= r * ; otherwise, n2 = n - n1 and r = r .

9. Repeat steps (2-3) for the second stage, n2 to determine y ; otherwise y

= O.

The

h

power of the test, 1-

fJ

Z)(x+y:s;r)
is constmcted such that 1- fJ = -"i==.!.l_ _ _ __
b

10. Repeat steps 2-6 for the null response rate. Given the new sample size, the critical
values determined using the alternative response are used.

11. If

p;:::: .30 , then n2 = n * -n1 and r

= r * ; otherwise,

n2 = n - n1 and r

h

Z)(x+y>r)
12. The size of the test or ais constmcted such that a=....:..i=....:..l_ _ _ __
b
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=r .

13. Repeat steps 1-12 for 10,000 iterations of different response profiles that satisfy
the weighted average given the weight profile. The trial errors given a weight
profile are then constructed using (20) where s = 10,000.

14. Repeat all steps for each weight profile,
w = {( .1,.9), (.2,.8), (.3,.7) ,(.4,.6), (.5,.5)} .

This algorithm results in the estimates of the trial operating characteristics given a
specific weight profile and any possible response profile satisfying the weighted average
constraint.

5.2.3

Results
Under latent heterogeneity, the appropriate form of heterogeneity is generalized

response heterogeneity. Under GRH, no information is known a priori on the source of
the heterogeneity. A two subgroup trial was simulated under GRH. Table 9 shows the
results given 10,000 simulations of weight*response profiles satisfying the weighted
average response rate constraint for the following parameters
1[0

= .30; 1[1 = .45;

a = .10; f3 = .20 .

The errors reported are the percentage of times the individual weight*response
profile errors crossed the target error boundaries in the inappropriate direction,

a > a and
b

a 2HA

and

Pb

> f3 where the weight*response type I error for the bth simulation is

as denote the type I error for the Adaptive and Simon designs.
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a

As with the

b .

Simon simulations, the expected value of the size and power are very close to the targets,
but it is the range that is more clinically important or as a proxy, the percentage above the
target error bounds.
Table 9 Simulated error estimates for various weight profiles with target errors of

(a,p) =(.1,.2) and (Jro,JZJ =(.30,.45).
WI

0.1
0.2
0.3
0.4
0.5

w2

I

a2HA

fJ2HA

as

Ps

0.9
0.8
0.7
0.6
0.5

.8
.6
.4
.2
0

0
0
0
0
0

0.18
0.17
0.14
0.05
0

0.22
0.l5
0.08
0.04
0

0.40
0.40
0.30
0.28
0

The adaptive design maintains the target type I error under all levels of
heterogeneity, e.g. weight profiles. The error increases as the heterogeneity imbalance
increases, but is below the target type II error. This is not the case with the Simon
design. From the simulations in section 5.1, the divergence from the target is marginal,
within, for example, fJ ± .05, but under the conduct of these type of trials, any divergence
from the target is the wrong direction is clinically substantial.
The Simon design does meet the target errors with an equal weight profile. As the
heterogeneity imbalance increases, the percentage of trials under a specific weight profile
that exceed the target error bounds increases. In the case of extreme weighting of the
subgroups, 1=.8,40% of the trials will not have a minimum of 80% power with 22% of
the trials oversized which can result in a successful Phase II trials but be the cause of a
failed Phase III trial.
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A second consideration of Phase II trials is the expected sample size of the trial.
Given a weight profile, summary statistics can be computed for the expected sample size
under heterogeneity for the 2HA design which relate the mean, standard deviation and
confidence intervals for the total sample size and expected sample size EN following (5)
where the mean or confidence interval is substituted for n,

EN(Ho) = ~ +(1- PET)(n -~)
Given

(Jro, Jr1 ) =(.30, .45)

and

(a,,8) = (.10,.20) , the Simon trial design results in

the following parameters and operating characteristics,
(~,n, PET, EN) = (20,55,.6070,41.24) under the optimal design. Under the Adaptive

design, the PET remains the same. Given 10,000 simulations of weight*response
profiles for each weight profile, the sample size summary statistics are listed in table 11.
Table 10 Sample sizes under the 2HA design

n[sd]

EN(Ho I I)
.8 70 [7] (55, 105) 50.37
.6 63 [ 6] (55, 105) 45.98
.4 59 [4] (55,102) 43.94
.2 58 [3] (55,98)
42.83
0 57 [3] (55,100) 42.59
I

Range

95% CI for EN
(41.62,59.11)
(38.78, 53.18)
(38.82,49.05)
(39.50,46.18)
(39.49,45.69)

Under the extreme case of heterogeneity imbalance, 1=.8, the 2HA design
results in an average increase of 27% of the Simon sample size with a corresponding 49%
increase in the expected sample size to control the trial errors at the target errors. As the
heterogeneity imbalance decreases, the expected sample size decreases as does the mean
sample size. In the case of no heterogeneity imbalance, the 2HA design only increases
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(56)

the sample size by 2 with an increase in the expected sample size of -1. This provides a
justification for allowing the type I error to be inflated for the heterogeneity test. If
heterogeneity is detected where none is truly present, the trial will only lead to a minimal
increase in sample size.
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CHAPTER 6
CONCLUSIONS AND FUTURE DIRECTIONS

6.1

Summary and conclusions
The primary purpose of a Phase II trial is to estimate if a treatment has a clinically

meaningful effect on a group of patients for further more targeted testing. Generally, ex

vivo evidence exists which provides evidence that the treatment does have efficacy on
either tissue samples or cell lines. The purpose of the Phase II trial is to demonstrate this
efficacy on a small subset of the affected patient population. If the Phase II trial is
successful, then either more targeted Phase II trials are conducted or the treatment moves
on to Phase III testing. Phase III testing provides the definitive answer as to the efficacy
of a treatment.
Phase II trials have some unique properties not seen in the earlier or later phases
of clinical trials. The trials are a single arm with no control arm. Though there is a move
towards Phase II trials with a randomized design with control and treatment arms, the
majority of Phase II trials are still single arm. The sample size in these trials is small,
from only 10 patients up to 120 patients. As such, Phase II trials only estimate a
response, and the larger Phase Ills are used to define the response. As the name suggests,
the type of trial is early in the drug development so historical information on the efficacy
of the treatment or the patient population may be lacking.
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All trials, Phase I-IV, rely on some homogeneity of the population to draw
inferences. In a Phase III trial or a randomized Phase II trial, the control and treatment
arms are expected to be similar, e.g. homogeneous in response. This is not always
possible in a Phase II trial. With only one arm, the homogeneity does not rest between
two samples, e.g. two trial arms, but rests on the homogeneity of the response in a single
population. The single population being tested, through the response rate, must be
homogeneous. Phase Ills do not need this assumption; only that homogeneity exists
between samples. For example, a Phase III or randomized Phase II can have multiple
subgroups in the trial, each with a unique response rate. As long as the distribution of the
subgroups is the same across the two arms, the homogeneity assumption is met. In a
Phase II trial, no comparison can be made, so subgroups cannot exist. All patients must
come from the same population with the same response. This assumption can be lacking
in actual trial practice and poses a substantial hurdle to accurate inferences from said
trials.
The most common Phase II trial design is the Simon Phase II designs as
described in section 2.1. These designs rely on a homogeneity assumption in the
response in order for the trial data to fit the model distribution of the trial parameters, the
Binomial distribution. In practice, subgroups may exist causing a divergence in the trial
data from the Binomial distribution. A large number of Phase II trials fail. It is
paramount to determine why these trials have such a high failure rate. In examining the
problem, multiple failure modes can be suggested, 1) the trial fails due to inaccurate
estimation of the true response rate, 2) the trial fails due to difference in the patient
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population cells and ex vivo cell lines, 3) the trial fails due to the use of a homogeneous
trial design when heterogeneity exists. This paper has focused on third failure mode.
Response heterogeneity can be constructed from a set of subgroups in the
population with subgroups having either unique response rates or unique etiologies of
their response rates. This paper provided a model for heterogeneity to quantify the
effects of heterogeneity on trial designs. The model was applied to the popular Simon
design and the Simon design was shown to have inflated errors beyond the target errors
rates across all three classes of heterogeneity. This is a standard practice in clinical trials,
subgroups are known to exist but for simplicity and to minimize patient resources, a
single trial is conducted using an averaged response with the Simon designs. Intuitively,
the inflation of error would be expected when a simple average is used to combine a set
of subgroup response rates into a homogeneous response rate. Under simple averaging,
there is no weighting to the average, but in fact, the population may have a specific
weighting profile. Hence, the simple average response rate may substantially diverge
from the true weighted population response rate.
To correct for this, weighted averages were also applied to the Simon designs.
In theory, the weighted average would correspond to the weighted average of the
population and correspond to a homogeneous response rate mathematically. This would
hold true except for one issue. The response is a weighted sum of binomials, but the
weighted sum of binomials is not binomial. Hence, the use of a binomial model
distribution may not be appropriate. The simulation results confirm this fact. While the
expected value of the errors across simulations, given a weight profile, usually did
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maintain the target errors, the range of actual errors crossed the target error bounds.
Specific weight*response profiles would exceed the target error bounds. In trial conduct,
any divergence is substantial since the trial is designed to never exceed the target error
bounds.
From a clinical interpretation using the expected value under heterogeneity is not
valid as a measure of the trials errors. Trial designs must maintain a target error for every
specific weight*response profile or within an allowable error level. The Simon designs
do not have this operating characteristic under heterogeneity. Hence, even under
weighted averages, the Simon design will not maintain the target errors. This provides
solid evidence that the Simon trial design may be a source of the high failure rates of
Phase II trials. Under homogeneity, the Simon design is the most efficient design, but the
design was not constructed to handle heterogeneity.
In order to develop a new design to handle heterogeneity, multiple current
methods were evaluated. All of the methods that have been developed in the past few
years suffer from a limiting factor, the composition of the subgroups must be known in
advance. It can be argued that if subgroups are known to exist, the most conservative
path is to conduct separate trials for each subgroup. This is a second common practice, in
opposition to averaging, conduct multiple trials. This can lead to a substantial increase in
trial resources which may be a motivating factor for using an averaged response.
In practice, subgroups are not generally known at such an eady stage of a
treatment's efficacy exploration. Failed Phase lIs provide solid evidence for future Phase
II's with the same or similar treatment. As more Phase II's are conducted a better image

66

of the treatments efficacy is refined. This approach uses the accumulation of trials to
accumulate and refine knowledge on the existence and composition of subgroups, but is
costly when evaluating patient and financial resources. Ethically, if a more optimal
solution to the allocation of patient resources exists, then this optimal method should be
utilized. When no information is available at the beginning of trial conduct, the type of
heterogeneity is known as latent heterogeneity and corresponds to the generalized
response heterogeneity class of the heterogeneity model. This would correlate to the first
conduct of a Phase II trial. We suggest a more optimal method than conducting multiple
Phase II trials to refine efficacy estimates.
We have developed a new Phase II design that can handle latent response
heterogeneity with a modest increase in the sample size. The new design works by
incorporating the trial structure, a two stage process, and the data structure, subgroups,
into the model distribution of the trial parameters, the Beta-Binomial posterior predictive
distribution. The predictive posterior form is chosen to account for the two stage process
of the trial. The trial starts as a standard Simon design with Simon design parameters.
After the first stage has concluded, the trial data, a single grouped sample, is tested for
the existence of subgroups using an unsupervised classification algorithm. Then a
heterogeneity test is computed. If heterogeneity is detected, the trial's overall sample
size is increased by an empirically determined variance inflation factor.
The variation inflation factor is the empirical estimate of the product of the
magnitude of the response profile and the magnitude of the weight profile from the first
stage conduct. This method to increase the sample size seems very intuitive. The
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response heterogeneity can be decomposed into two sources which differ in
heterogeneous responses as compared to a homogeneous response, weight and response
profiles versus no weights and a single fixed response rate. Multiple other methods were
tried, but no method was able to consistently maintain the errors across all possible
weight profiles. The trial uses the posterior predictive Beta-Binomial distribution to
construct a new critical value by an exact method to determining the trial errors.
This new design, the 2-stage heterogeneity adaptive design, is shown to never
exceed the target trial errors. Even with an extreme heterogeneity imbalance, the target
trial errors are maintained. Under small or no heterogeneity imbalance or a small
difference in the response magnitude, there is only a marginal increase in the total or
expected sample size. This fact gives credence to the earlier use of a very liberal
heterogeneity test. With only a single grouped sample, no single heterogeneity test is
reliably going to result in robust inferences or always control the type I error, the
probability of determining heterogeneity when one exists. The chosen heterogeneity test,
the Farrington test, does maintain an acceptable level of power, >80% which is of
primary concern. If one does not detect heterogeneity when it truly exists, then the
Simon design is not appropriate. The scalable sample size based on the variance inflation
factor results in only minimal increases in sample size when heterogeneity is detected,
but truly not existent.
A limiting factor of this design is the determination of subgroups. A full
exposition of how to determine subgroups from an unsupervised approach is beyond the
scope of this paper, but the limitations imposed by this issue are understood. A second
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limiting factor is the stopping of the trial to determine the existence of subgroups. Many
designs have been developed which maintain the operating characteristics of the Simon
design but allow for continuous patient accrual with no between stage stopping. Many
clinicians may feel that waiting a few weeks between stages is too long, but in the end,
this extra time may result in a saved trial. As such, the determination of the classifier and
the time is takes to determine the classifier are limitations to this design.
In conclusion, the 2-stage heterogeneity adaptive design maintains the target
errors of a binary 2-stage single arm trial. The trial design preserves the desirable
operating characteristic of the Simon design, moderate probability of early termination,
without a substantial increase in trial resources. The increase in trial resources is
determined by the first stage results. If subgroups are detected and the imbalance in these
subgroups either in weights or response rates is high, then the increase in the overall
sample size compared to the Simon trial will be substantial. In no way, it is claimed to be
the minimum necessary increase in sample size, but through simulation was shown to
always be adequate. This method works under the full range of possible heterogeneity
which will at times result in larger than necessary sample sizes.

6.2

Direction for future work
This design presents multiple areas of limitation that need to be addressed. The

primary limitation is the detection of subgroups. More work is needed to indentifying an
unsupervised classification algorithm that can work under the small sample sizes in the
first stage of a Phase II clinical trial. An unsupervised algorithm presents a very practical
case since the source of heterogeneity in many diseases is determined to be genomic. If a
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classifier is used that does not have perfect classification, then an additional source of
variation is introduced into the problem. In this case the VIP becomes the product of
both the weight and response profiles and the classification accuracy. Less accurate
classifiers will result in an increase in the sample size. Secondly, a better test for
heterogeneity that preserves the type I error would also be an optimal improvement.
The detection of only two groups is adequate for trials where the sample size is
relatively small, but in larger Phase II trials, the detection of more than two groups should
be possible. Understanding what the limitations are for a higher detection number and
robust tests are necessary. The use of the Beta-Binomial posterior predictive distribution
provides a necessary correction factor for heterogeneity in the second stage of the trial.
Work needs to be conducted to determine if it would be more optimal to not start as a
Simon Design, but conduct the entire trial using the posterior predictive distribution.
A final improvement would be to include local hypothesis tests. The most
desirable attribute of the Bayesian ANOV A and hierarchical methods is the sharing of
information across subgroups and allowing for subgroup specific stopping or acceptance.
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